Personalized mRNA Vaccine Reduces Melanoma Recurrence and Metastasis Risk
The Istituto dei tumori di Milano has emerged as one of the Italian centers to administer an experimental personalized mRNA cancer vaccine, marking a significant milestone in high-risk melanoma treatment trials. According to clinical trial disclosures reported by LaPresse and Corriere della Sera, the administration occurred as part of the ongoing Phase III INTerpath-001 international study evaluating the therapeutic candidate intismeran in combination with standard immunotherapy.
- Italy enrolled approximately 200 of the global trial participants across four clinical centers, including the Istituto dei tumori di Milano.
- The therapeutic mRNA vaccine is custom-manufactured for each patient following surgical resection by identifying up to 34 distinct neoantigens via artificial intelligence algorithms.
- Phase III trial endpoints demonstrate a statistically significant reduction in recurrence and distant metastasis when combining the vaccine with pembrolizumab compared to immunotherapy alone.
Clinical Trial Design and Patient Selection Criteria
The INTerpath-001 trial evaluates a therapeutic intervention designed to prevent disease recurrence in patients diagnosed with high-risk melanoma who have undergone radical surgical resection. Unlike prophylactic vaccines meant to prevent disease in healthy populations, this mRNA platform relies on the molecular profiling of an individual patient’s excised tumor tissue. Laboratories sequence the tumor biopsy to identify up to 34 immunogenic neoantigens, which serve as foreign targets to train the host immune system.
According to Giuseppe Curigliano, president of the European Society for Medical Oncology (ESMO) and vice-scientific director at the European Institute of Oncology (IEO) interviewed by Corriere della Sera, the study randomized patients globally. The control arm received pembrolizumab monotherapy, while the experimental arm received the combination of pembrolizumab and the personalized mRNA vaccine, intismeran. Trial data indicate that this dual approach successfully meets its primary endpoints regarding recurrence-free survival.
The Italian Contribution and Multicenter Collaboration
Italy played a foundational role in the global trial execution. Paolo Ascierto, an oncologist at the Pascale in Naples and international steering committee member, noted to LaPresse that Italy contributed the largest patient cohort of any participating nation, registering roughly 200 patients out of the total worldwide. Alongside the Istituto dei tumori di Milano and the Pascale in Naples, the network of Italian clinical sites includes the Gemelli in Rome and the Center for Immuno-Oncology in Siena.
Future Directions and Translation to Other Malignancies
The success of the Phase III melanoma trial opens distinct avenues for broader oncological applications. Clinical trials are currently underway evaluating mRNA vaccination strategies in lung, kidney, bladder, and pancreatic cancers, according to published clinical updates.
As the medical community awaits the formal presentation of comprehensive Phase III data at the upcoming European Society for Medical Oncology congress, healthcare institutions are reviewing supply chain and diagnostic workflows.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*